Neutralization of B-Cell Activating Factor (BAFF) by Belimumab Reinforces Small Molecule Inhibitor Treatment in Chronic Lymphocytic Leukemia

SIMPLE SUMMARY: Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in Western countries. Despite the substantial progress achieved by the recent introduction of the novel small molecule inhibitors idelalisib, ibrutinib and venetoclax in CLL treatment, therapy resistance occurs fr...

Descripción completa

Detalles Bibliográficos
Autores principales: Tandler, Claudia, Schmidt, Moritz, Heitmann, Jonas S., Hierold, Julia, Schmidt, Jonas, Schneider, Pascal, Dörfel, Daniela, Walz, Juliane, Salih, Helmut R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7598196/
https://www.ncbi.nlm.nih.gov/pubmed/32977449
http://dx.doi.org/10.3390/cancers12102725

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7598196/
https://www.ncbi.nlm.nih.gov/pubmed/32977449
http://dx.doi.org/10.3390/cancers12102725

Ejemplares similares